News | September 17, 2019

Edgewise Therapeutics Closes $50 Million Series B Financing – Financing to Support Advancing Company’s Lead Product Candidate for Muscular Dystrophy- Boulder, Colo., (September 17, 2019) – Edgewise Therapeutics, a preclinical company developing small molecule...

News | September 5, 2019

BrightInsight Raises Significant Capital to Enhance its Regulated Digital Health Platform and Accelerate Global Commercialization Today we announced the exciting news that BrightInsight raised significant capital from top healthcare venture capital firm, New Leaf...

News | August 14, 2019

Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock WALTHAM, Mass.–(BUSINESS WIRE)–Aug. 14, 2019– Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key...

News | August 13, 2019

Deciphera Pharmaceuticals Reports Positive Updated Phase 1 Data for Ripretinib in Gastrointestinal Stromal Tumors – Data from Phase 1 Study Supports Ongoing INTRIGUE Phase 3 Clinical Study in Patients with Second-line GIST – – Median Progression Free...

News | July 29, 2019

ARVINAS APPOINTS RONALD PECK, M.D. AS CHIEF MEDICAL OFFICER NEW HAVEN, Conn., July 29, 2019 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, announced today the...

News | August 1, 2019

Neuronetics® Announces First TMS Patient Treated Under New Japan Reimbursement Policy Reimbursement for Company’s non-drug depression treatment, NeuroStar® Advanced Therapy, enables access for depression sufferers in Japan MALVERN, Pa., Aug. 1, 2019 /PRNewswire/...